NCT05011188View on ClinicalTrials.gov

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 19, 2022

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Metastatic Castration-resistant Prostate CancerProstate Cancer
Interventions
BIOLOGICAL

FOR46

Given intravenously (IV)

BIOLOGICAL

Enzalutamide

Given orally (PO)

DRUG

Pegfilgrastim

Given subcutaneously (subQ)

PROCEDURE

Blood Samples

Blood samples will be taken for correlative studies

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors
All Listed Sponsors
collaborator

Fortis Therapeutics, Inc.

INDUSTRY

collaborator

FibroGen

INDUSTRY

lead

Rahul Aggarwal

OTHER